Synchron Raises $200 Million Series D to Advance Brain-Computer Interface Technology
Synchron announced a $200 million Series D funding round to accelerate the commercialization of its Stentrode™ brain-computer interface (BCI) platform. The investment will also support the expansion of the company's AI and engineering teams in New York and San Diego.
Stentrode™ Endovascular Electrode Array
Contact Information
Media inquiries: Kimberly Ha — [email protected]
"The new funding will help bring the Stentrode™ closer to widespread clinical use and enhance our AI capabilities to improve patient outcomes."
Synchron's Series D round strengthens its position in the evolving BCI market by supporting research, product development, and geographic growth.
Author's summary: Synchron’s $200 million funding aims to propel the Stentrode™ BCI technology into broader clinical application while growing its AI and engineering teams in key U.S. locations.